
CNTX Stock Forecast & Price Target
CNTX Analyst Ratings
Bulls say
Context Therapeutics Inc., a clinical-stage biopharmaceutical company focused on innovative treatments for hormone-dependent cancers, has indicated that initial dose escalation data for its lead program, CTIM-76, shows promising clinical activity and safety, supporting further enrollment across various solid tumors. The company's financial position appears robust enough to sustain operations through critical clinical readouts anticipated in 2026, thereby alleviating immediate financing concerns and maintaining investor interest driven by data outcomes. With CTIM-76's demonstrated potency and selectivity for CLDN6, the potential for superior anti-tumor activity could enhance the company's valuation and attract partnership opportunities, further solidifying a positive outlook for the stock.
Bears say
Context Therapeutics Inc. has experienced a significant decline in cash reserves, finishing 2025 with $66.0 million compared to $94.4 million at the end of 2024, indicating potential financial instability. The company reported a net loss of $9.7 million for Q3 2025, despite reduced research and development expenses, and forecasts suggest a need for approximately $250 million in additional financing through 2041. Furthermore, Context faces multiple operational risks, including safety concerns in clinical programs, competitive pressures in the market, regulatory hurdles, and a risk of stock delisting if trading conditions do not improve.
This aggregate rating is based on analysts' research of Context Therapeutics LLC and is not a guaranteed prediction by Public.com or investment advice.
CNTX Analyst Forecast & Price Prediction
Start investing in CNTX
Order type
Buy in
Order amount
Est. shares
0 shares